Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers is a research paper published in Nanoscale (2022). On theSindex it has a DataRank of 0. It has been cited 31 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: R01CA253627
National Cancer Institute
Grant: U01CA198892
National Cancer Institute
Grant: P30CA043703
National Institutes of Health
Grant: S10-RR031845
NCRR NIH HHS
Grant: S10 RR031845
National Institutes of Health
Grant: 3P30CA043703-20S1
Case Comprehensive Cancer Center Support Grant
National Institutes of Health
Grant: 5R01CA253627-05
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis
National Institutes of Health
Grant: 5U01CA198892-03
Treatment of glioblastoma using chain-like nanoparticles
FWCI
2.12
Citation Percentile
0.9%
Influential Citations
1
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals